UK Drug Prices Worst in Europe – Mounjaro Maker Claims
- * Pharma Investment Pullback: The UK's pharmaceutical industry is facing significant challenges,with over £1.8 billion worth of projects being pulled or paused this year alone.
- In essence, the article highlights a growing crisis in the UK pharmaceutical sector, driven by investment uncertainty and pricing pressures.
Here’s a summary of the key points from the provided text:
* Pharma Investment Pullback: The UK’s pharmaceutical industry is facing significant challenges,with over £1.8 billion worth of projects being pulled or paused this year alone. In total, 13 major projects or companies have been negatively impacted sence 2022.
* Specific Examples:
* Bristol Myers Squibb is threatening to not sell a new schizophrenia drug in the UK.
* AstraZeneca scrapped a project in Liverpool.
* Eli Lilly shelved a lab in London and significantly increased the price of its weight-loss drug, Mounjaro (up to 170% for private buyers).
* Industry Concerns: Executives like Ricks are stating that the UK is becoming an “unattractive environment” for pharmaceutical investment due to these issues.
* Interactive Graphic: The article includes an interactive graphic illustrating pharma site closures.
* Newsletter Promotion: There’s a promotion for “Buisness Today,” a daily business news newsletter.
In essence, the article highlights a growing crisis in the UK pharmaceutical sector, driven by investment uncertainty and pricing pressures.